Please login to the form below

Not currently logged in
Email:
Password:

Onyx Pharma appoints John Osborn SVP global corporate affairs

Joins from Dendreon to lead public and government affairs activities

Dendreon's John Osborn has joined Onyx Pharmaceuticals as senior VP, global corporate affairs.

In his new role at the US-based biopharma, he will lead the company's public and government affairs activities, as well as key stakeholder relationships.

Osborn's most recent position was executive VP, general counsel and secretary at Dendreon, which markets cancer vaccine Provenge.

Prior to his time at Dendreon, he held similar roles at US Oncology and Cephalon.

He also spent time serving with the US Department of State and was a member of the bipartisan United States Advisory Commission on Public Diplomacy in 2008.

“As a lawyer, policy advocate and former diplomat, John brings a diverse and extensive background to Onyx, with broad experience across the life sciences industry and the US government,” said Dr Anthony Coles, president and CEO of Onyx.

“John is a proven leader and his unique expertise aligns well with our plan for global growth as a multi-product company reaching patients around the world.”

20th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Medius Deal Watch
Deal Watch December 2016
Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up...
The Young Dementia Network - much more than a logo
Welcome to the second and final part of my two-part blog....
Patient-centred care innovation in dementia: a conversation with Neil Maiden
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators...

Infographics